The 2024 RETpositive/LUNGevity Translational Research Award supports translational research that have a direct impact on the outcomes of patients with advanced RET-positive cancer. In keeping with the mission of the RETpositive group, proposals focusing on multiple types of RET-positive cancers or with a clear impact on multiple types of RET-positive cancers will be given priority. Applicants must hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university, and have completed a postdoctoral training fellowship. Applicants may be based anywhere in the world.
The award provides up to 100,000 USD over 2 years (up to 10% indirect costs).
Letters of intent are due on February 9, 2024 and full invited applications are due on May 8, 2024.
May 8, 2024